Background Type B aortic dissections(TBAD)are catastrophic conditions with high complication and mortality rates. This study aimed to investigate the prognostic significance of CDK13 expression in patients with type B...Background Type B aortic dissections(TBAD)are catastrophic conditions with high complication and mortality rates. This study aimed to investigate the prognostic significance of CDK13 expression in patients with type B aortic dissection(TBAD)undergoing thoracic endovascular aortic repair(TEVAR). Methods Totally 56 patients with TBAD undertaken TEVAR were included in this study,CDK13 expression was detected in blood samples which were collected from vein before angiography. We reviewed hospital readmission records and outpatient clinic interviews for possible events. The primary endpoint was long-term all-cause mortality. The secondary endpoints were in-hospital major adverse clinical events(MACEs). Results A total of 56 patients(mean age 61.2±12.4 years)were included in the study. We divided the patients into 2 risk levels(28 patients for each level)according to the median of CDK13 expression. The in-hospital mortality(3.6% vs. 14.2%,P<0.05)and MACEs(10.7% vs. 39.3%,P<0.05)were significant higher in patients with high CDK13 level(≥ median).Conclusions The expression level of CDK13 could be considered as a relatively simple tool for pre-TEVAR risk stratification.[S Chin J Cardiol 2019;20(2):121-124]展开更多
基金supported by Guangdong Natural Science Foundation(No.2018A030313029)
文摘Background Type B aortic dissections(TBAD)are catastrophic conditions with high complication and mortality rates. This study aimed to investigate the prognostic significance of CDK13 expression in patients with type B aortic dissection(TBAD)undergoing thoracic endovascular aortic repair(TEVAR). Methods Totally 56 patients with TBAD undertaken TEVAR were included in this study,CDK13 expression was detected in blood samples which were collected from vein before angiography. We reviewed hospital readmission records and outpatient clinic interviews for possible events. The primary endpoint was long-term all-cause mortality. The secondary endpoints were in-hospital major adverse clinical events(MACEs). Results A total of 56 patients(mean age 61.2±12.4 years)were included in the study. We divided the patients into 2 risk levels(28 patients for each level)according to the median of CDK13 expression. The in-hospital mortality(3.6% vs. 14.2%,P<0.05)and MACEs(10.7% vs. 39.3%,P<0.05)were significant higher in patients with high CDK13 level(≥ median).Conclusions The expression level of CDK13 could be considered as a relatively simple tool for pre-TEVAR risk stratification.[S Chin J Cardiol 2019;20(2):121-124]
